Table 1.
Characteristics of the Study Population.a
| Non-TOF | Standard TOF | Improved TOF | |
|---|---|---|---|
| # Participants, total | 47 | 51 | 41 |
| −furosemide | 19 | 15 | 7 |
| + furosemide | 28 | 36 | 34 |
| Age, years, total (SD) | 67.9 (8.5) | 67.7 (7.0) | 68.4 (6.9) |
| −furosemide | 67.3 (7.6) | 65.7 (7.4) | 71.7 (5.3) |
| + furosemide | 68.2 (9.2) | 68.6 (6.7) | 68.4 (7.1) |
| Body mass index (BMI), total (SD) | 27.3 (4.6) | 26.1 (3.0) | 27.3 (4.2) |
| −furosemide | 27.7 (4.6) | 25.5 (2.4) | 26.1 (3.6) |
| + furosemide | 27.1 (4.7) | 26.4 (3.2) | 27.6 (4.3) |
| Height, cm, total (SD) | 179.9 (7.5) | 177.7 (6.1) | 177.5 (7.1) |
| −furosemide | 179.4 (8.5) | 176.9 (7.2) | 180.2 (8.2) |
| + furosemide | 180.2 (6.7) | 178.1 (5.6) | 176.9 (6.8) |
| Weight, kg, total (SD) | 88.5 (16.1) | 82.4 (10.7) | 86.3 (14.4) |
| −furosemide | 89.3 (14.6) | 79.5 (7.0) | 84.8 (14.4) |
| + furosemide | 88.2 (17.4) | 83.7 (11.8) | 86.1 (14.6) |
| PSA, ng/mL, total (SD) | 12.0 (16.1) | 9.8 (13.1) | 11.0 (16.8) |
| −furosemide | 13.6 (9.9) | 9.8 (11.5) | 13.9 (17.9) |
| + furosemide | 8.4 (19.1) | 11.7 (13.8) | 10.6 (16.8) |
| Tracer dose, mCi, total (SD) | 5.6 (1.2) | 5.3 (0.8) | 6.4 (0.9) |
| −furosemide | 5.3 (0.6) | 5.4 (0.6) | 6.2 (0.8) |
| + furosemide | 6.1 (1.4) | 5.1 (0.9) | 6.4 (0.9) |
| Scan delay, minutes, total (SD) | 63 (11.3) | 62 (5.9) | 82.8 (20.5) |
| −furosemide | 61 (6.2) | 64 (5.0) | 80 (7.2) |
| + furosemide | 65 (13.6) | 60 (6.0) | 80 (22.4) |
Abbreviations: SD, standard deviation; TOF, time-of-flight.
a Continuous variables are expressed as mean (standard deviation).